The estrogen receptor: A structure-based approach to the design of new specific hormone-receptor combinations

Chemistry and Biology

Volumn 8, Issue 3, 2001, Pages 277-287

  Tedesco, Rosanna ^a   Thomas, James A ^b   Katzenellenbogen, Benita S ^b   Katzenellenbogen, John A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Estrogen receptor; Hormone specificity; Receptor specificity reengineering

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; LIGAND;

ANIMAL; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DESIGN; ENZYME SPECIFICITY; GENETICS; HUMAN; METABOLISM; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ESTROGENS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0035068096     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(01)00006-0     Document Type: Article

References (33)

1. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects the steroid binding characteristics and response to antoandrogens
2. A single amino acid that determines the sensitivity of progesterone receptor to RU486
3. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progestorone receptor
4. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen
5. Specific mutations in the estrogen receptor change the properties of anti-estrogen to full agonists
6. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domain
7. Human estrogen receptor ligand activity inversion mutants: Receptors that interpret anti-estrogens as estrogens and estrogens as anti-estrogens and discriminate among different anti-estrogens
8. Molecular basis of agonism and antagonism in the oestrogen receptor
9. Redesigning small molecule-protein interfaces
10. Modifying ligand specificity of gene regulatory proteins
11. Development of gene-switch transgenic mice that inducibly express transforming growth factor β1 in the epidermis
12. Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding
13. Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and anti-estrogens
14. Determinants of ligand specificity of estrogen receptor-α: Estrogen versus androgen discrimination
15. Cell-specific calcineurin inhibition by a modified cyclosporin
16. The estradiol pharmocophore: Ligand structure-estrogen receptor binding affinity relationship and a model for the receptor binding site
17. Inhibition of rat liver microsomial lipid peroxidation elicited by 2,2-dimethylchromenes and chromans containing fluorinated moieties resistant to cytochrome P-450 metabolism
18. Controlling protein association and subcellular localization with a synthestic ligand that induces heterodimerization of proteins
19. Three-part inventions: Intracellular signaling and induced proximity
20. Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket
21. Engineering Src family protein kinases with unnatural nucleotide specificity
22. Generation on monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach
23. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum
24. Generation of conditional mutants in higher eukaryotes by switching between the expression of two genes
25. Diverse strategies for tetracycline-regulated inducible gene expression
26. Ecdysone-inducible gene expression in mammalian cells and transgenic mice
27. Engineering novel specificities for ligand-activated transcription in the nuclear hormone receptor RXR
28. Selective regulation of gene expression using rationally modified retinoic acid receptors
29. Random mutagenesis of human estrogen receptor ligand binding domain identifies mutations that decrease sensitivity to estradiol and increase sensitivity to a diphenyl indenol compound; basis for a regulatable expression system
30. Generation of estrogen receptor mutants with altered ligand specificity for use in establishing a regulatable gene expression system
31. Photoaffinity labels for estrogen binding proteins of rat uterus
32. Rapid and efficient site-specific mutagenesis without phenotypic selection
33. The carboxy-terminal F-domain of the human estrogen receptor: Role in the transcriptional activity of the receptor and the effectiveness of anti-estrogens as estrogen antagonists